Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameAk Medical
Stock Code01789
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是中國第一家且唯一一家將3D打印技術商業化且應用於骨關節及脊柱置換植入物的醫療器械公司,設計、開發、生產及銷售骨科植入物,專注於髖關節及膝關節置換植入物,亦分銷第三方骨科產品。
Listing Date2017-12-20
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)北京市 昌平區科技園區 白浮泉路10號
Business Address (Hong Kong)香港 皇后大道東183號 合和中心54樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websiteak-medical.net
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 1.75 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2017-12-07 to 2017-12-12
Global Offering Shares250,000,000 shares
HK Public Offer Shares (Initial)25,000,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)225,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,000,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 437,500,000

Stock Connect Inclusion Analysis

HK Market Cap HK$ 5.94B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利约人民币77.3百万元
Period-End Cash Balance人民币160.6百万元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 2014201520162017-06
Revenue 148,278206,164270,777162,517
Cost of sales -46,933-64,108-83,466-50,814
Gross profit 101,345142,056187,311111,703
Other income and gains, net 1,7788237931,854
Selling and distribution expenses -17,416-28,782-36,229-19,660
Administrative expenses -12,377-22,262-38,115-18,276
Operating profit 57,79172,95793,37057,692
Net finance costs 2,5062,9941,657478
Profit before tax 60,29775,95195,02758,170
Income tax expense -8,576-11,044-17,701-8,120
Profit for the year 51,72164,90777,32650,050
Profit attributable to owners 51,72164,90777,32650,050
Balance Sheet
Item 2014201520162017-06
Cash and cash equivalents 43,161100,094160,597165,628
Trade and bills receivables 24,04857,86181,53089,721
Inventories 34,72058,40067,80584,848
Total current assets 177,037223,973322,457353,406
Total assets 212,647283,750405,535459,827
Total current liabilities 51,065100,81999,034127,468
Total liabilities 56,696106,812111,142139,260
Total equity 155,951176,938294,393320,567
Equity attributable to owners 155,951176,938294,393320,567
Cash Flow Statement
Item 2014201520162017-06
Net cash from operating activities 51,09236,30269,64356,479
Net cash from investing activities -16,02044,462-27,166-26,901
Net cash from financing activities -30,600-23,91114,037-23,403
Net increase in cash 4,47256,85356,5146,175
Depreciation of PP&E 4,2764,6417,8655,178
Amortisation of intangible assets 247449907588
Purchase of PP&E -6,063-24,367-28,371-24,363
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 2.64
First Day OpenHK$ 1.75
First Day Change50.86%
First Day Volume214153000.0
First Day Turnover456984000.0
Use of Proceeds
1、約41.0%將主要用于我們常州設施的建設,并在較少程度上升級我們于北京現有的設施,及為常洲設施及我們于北京現有的設施收購新設備; 2、約21.0%將用作開發及升級我們的3D打印產品及醫工交互平臺; 3、約15.0%將用作其他研發活動; 4、約15.0%將用于撥付能夠補充我們的現有產品組合、技術及業務增長的潛在收購及發展戰略聯盟; 5、約8.0%將用作一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Overall Coordinators (1)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Joint Bookrunners (1)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Joint Lead Managers (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 国泰君安证券(香港)有限公司 CE ABY236

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman李志疆—
Company Secretary韓鈺、李昕穎—
No director data available.

Major Shareholders

Major Shareholders & Holdings李先生通過喜馬拉亞及配偶權益合共持有約59.53%股份,張斌女士因配偶權益被視為持有約59.53%股份;張朝陽先生通過陽峰持有約6.74%股份;OrbiMed Asia持有約7.50%股份。
About this page

This page shows Ak Medical (01789) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect